Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in metastatic urothelial carcinoma (FIGHT-201)
NCT02872714Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2017
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of pemigatinib in urothelial carcinoma (UC) (3 cohorts), sponsored by Incyte. Primary endpoint: Objective Response Rate up to 1138 days. Started Jan 2017; status: completed.
02
Drugs
pemigatinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02872714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872714.